Skip to main content
Top
Published in:

24-05-2024 | Encephalitis | Case Report

Moyamoya disease in a 5-year child secondary to MOG antibody-positive cerebral cortical encephalitis

Authors: Mahesh Venkatachari, K. S. Ashwanth, Yugandhar Samireddypalle, Thirunavukkarasu Arun Babu

Published in: Child's Nervous System | Issue 9/2024

Login to get access

Abstract

A 5-year-old girl presented with complaints of fever, left-sided hemiparesis, and left upper motor neuron facial nerve palsy following oral polio booster dose vaccination. She had a past history of fever with altered sensorium with complete resolution at 3 years of age. Cerebrospinal fluid evaluation and stool examination were inconclusive. MRI with MRA showed T2 hyperintensities of the right fronto-temporo-parietal cortex with diffusion restriction and occlusion of bilateral internal carotid arteries and collateral formation suggestive of Moyamoya disease with cerebral cortical encephalitis. Evaluation of encephalitis revealed positivity for anti-myelin oligodendrocyte (MOG) antibodies. She showed a good response to intravenous immunoglobulin and pulse steroids with resolution of encephalitis and facial nerve palsy and improvement in the power of the left side of the body. We presume that the Moyamoya disease in this case is possibly secondary to myelin oligodendrocyte antibody-associated disease.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Moyamoya disease in a 5-year child secondary to MOG antibody-positive cerebral cortical encephalitis
Authors
Mahesh Venkatachari
K. S. Ashwanth
Yugandhar Samireddypalle
Thirunavukkarasu Arun Babu
Publication date
24-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 9/2024
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-024-06470-0

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest